Notably, FGF-23 estimated adverse cardiovascular outcomes in women with T2DM [139], and also, high levels of FGF-23 (and low of adiponectin) diagnosed GDM at the 3rd trimester [140] (Table 4). This evidence concerns the gene ADIPOQ and gestational diabetes.